Peter Maag, PhD, Chief Executive Officer
Dr. Maag has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining CareDx, Peter was President of Novartis Diagnostics based in Emeryville, California. He headed the expansion of the unit with worldwide growth in its blood screening business and established new ventures in molecular diagnostics. Peter also led one of Novartis’ key affiliates as Country President, Germany, and lived in a dynamically-growing and emerging market as Country President, Korea. At Novartis headquarters in Switzerland, he helped launch the Infectious Diseases franchise and served as the Head of Strategy for Novartis Pharmaceuticals. Prior to joining Novartis, Peter worked for 6 years at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Besides supporting various healthcare and tech companies in their growth efforts, he holds a supervisory board position at Phoenix Pharma SE and serves on the board of the Personalized Medicine Coalition in Washington, DC. Peter studied pharmaceutical sciences in Heidelberg and London, and received his PhD from the University of Berlin, Germany..
Michael Bell, Chief Financial Officer
Michael Bell brings over 20 years of international finance and accounting experience. Michael is the former CFO of Metabiota, an infectious disease risk analytics company. Previously, he served as the CFO of Singulex, a clinical diagnostics company, and has held leadership and executive positions within Novartis, including tenure as the CFO of Novartis Diagnostics, a global provider of blood screening solutions. Previously, Michael worked in public accounting at Ernst & Young and Deloitte. Michael holds a Bachelor of Science degree in Mathematics with Computing from the University of Leicester in the United Kingdom, and is a Fellow of the Institute of Chartered Accountants in England & Wales.
Paul Ciccolella, Senior Vice President, Global Operations
Paul Ciccolella brings 20 years of Engineering and Operations experience in the Life Sciences Tools industry. Before joining CareDx, Paul was Vice President, Engineering and Manufacturing at Pacific Biosciences, a global provider of Next-Gen Sequencing solutions. At PacBio he led the transfer and scale up of processes and product improvements for SMRT Cells (nanofabricated DNA sequencing chips) and managed a complex global manufacturing process. Prior to PacBio, Paul spent 11 years at Affymetrix in various roles of increasing responsibility in research and development, quality, and manufacturing, developing novel test methods that improved DNA microarray quality and laid the groundwork for future technology advancements. Paul studied Materials Science & Engineering, earning his Bachelor of Science from Cornell University and Master of Science from Stanford University.
Marissa Dixon, Vice President, Human Resources
Marissa Dixon has broad Human Resources experience in a range of high-growth, fast-paced industries. Over the last several years, she has specialized in the distinctive needs of the Biotechnology field.Prior to joining CareDx, Marissa served as the Vice President of Human Resources at Metabiota in San Francisco where her mission was to build an innovative Human Resources function and people programs to attract and retain high performing talent to the rapidly growing startup up focused on infectious disease data and analytics. Marissa has also held Senior HR Leadership roles in the SF Bay Area at DuPont Industrial Biosciences (formerly Genencor) and WageWorks. Marissa holds an M.S. in Human Resource Design and an M.A. in Psychology from Claremont Graduate University as well as an undergraduate degree in Social Sciences from Cal Poly San Luis Obispo.
Alexander L. Johnson,Vice President, Laboratory Solutions Business
Alex Johnson brings broad international business experience in pharma and clinical diagnostics. Prior to joining CareDx, Alex was Chief Operating Officer of BioGraph 55, a venture-backed immuno-oncology drug development company that uses advanced imaging analytics and machine learning to capture clinically relevant content from the tumor microenvironment. From 2009 to 2014 he was with Novartis, with roles at Novartis Diagnostics, a global provider of blood screening solutions and Novartis M&A based in Basel, Switzerland where he led acquisitions in oncology and diagnostics. Prior to Novartis Alex was with UBS Investment Bank in the Global Healthcare group. Mr. Johnson studied economics at Union College (NY) and received his M.B.A. in Finance from Columbia Business School.
Sasha King, Chief Commercial Officer
Sasha King brings over 10 years of diagnostics and genetic testing experience. Most recently she worked in companion diagnostics marketing at Genentech, and was a sales leader at Ariosa Diagnostics. While at Genentech, she worked on the launch of the first FDA approved cell free DNA test in oncology, the PD-L1 test launch, and the Foundation Medicine partnership. Sasha was an early member of the commercial team at Ariosa, a leader in the field of noninvasive prenatal testing (NIPT) which is now part of the Roche Group. She led the launch of their test into Asia Pacific and Canada. Sasha previously worked at Fletcher Spaght, a life science consulting and venture capital fund. Sasha received a bachelor of science in bioengineering from Massachusetts Institute of Technology and an MBA from Stanford Graduate School of Business.
David Sayer, PhD,Vice President, Global Transplant Laboratory Solutions
David Sayer, PhD, has 25+ years in the field of Immunogenetics/HLA. His professional career started as a Medical Scientist in a Clinical Immunology laboratory and Immunogenetics Research facility at Royal Perth Hospital. Realizing the best way to develop techniques to perform HLA typing by DNA sequencing was to do it commercially, he left the clinical laboratory system and co-founded Conexio Genomics with colleague, Damian Goodridge. Conexio grew to be a world leader in the development of innovative products and was acquired by Illumina in 2016. He worked with Illumina for 2 years ahead of joining CareDx in June as Vice President, Global Transplant Laboratory Solutions..
Reginald Seeto, MB.BS., President and CBO
Dr. Seeto is an experienced leader and has held executive leadership roles in both biotech and large pharma and across a broad range of functions. Before joining CareDx, Dr. Seeto was Chief Operating Officer at Ardelyx leading pre-launch efforts for tenapanor and corporate development where he completed a series of partnerships. Prior to this, Dr. Seeto worked at AstraZeneca/Medimmune and was a member of the MedImmune Executive Team. His responsibilities included leading corporate development and strategy, global strategic marketing and portfolio management for all therapeutic areas, as well as a country leadership role at AstraZeneca in Thailand. He started his career as a physician, during which time he performed a medical rotation in a renal transplant unit, before joining McKinsey and Company.
Robert N. Woodward, PhD, Vice President, Research and Development
Dr. Robert Woodward has led research and development projects in transplant diagnostics and gene expression discovery for over 20 years. Most recently at CareDx he was responsible for the bioinformatics, biostatistics, and laboratory teams that developed and validated AlloSure, an application of cell-free DNA to solid organ transplantation. Earlier in his career, he initiated biomarker discovery efforts with BioCardia and XDx and subsequently led the laboratory development of AlloMap, a gene expression test that has become an integral component of precise patient care in heart transplantation. During a post-doctoral fellowship at the Gladstone Institutes and University of California San Francisco, Dr. Woodward developed unique methods for analysis of gene regulation in vivo to study atherosclerosis. Following a bachelor’s degree in biology from Missouri State University, Dr. Woodward earned his Ph.D. in physiology at the University of Missouri-Columbia where he described the effects of a new transcription factor in the coordinate regulation of gene expression in response to steroids.
James Yee, MD, PhD, Executive Vice President and Chief Medical Officer
Dr. James Yee brings more than 25 years of research and development experience. Most recently, Dr. Yee served as Vice President and Head of Development for Celera Genomics, where he built the development organization at Celera South San Francisco and led clinical research and therapeutic development activities for cancer and immune-mediated inflammatory diseases. Prior to his work at Celera, Dr. Yee served as Vice President of Clinical and Pre-Clinical Research for the Inflammatory and Viral Diseases Unit at Roche Pharmaceuticals. In this role, he led the team responsible for selecting and evaluating compounds for clinical drug development and oversaw groups responsible for toxicology, drug metabolism, pharmacokinetics, bioanalytical chemistry, analytical chemistry, formulations, regulatory affairs, project management, and clinical research. Earlier in his career, Dr. Yee held a variety of research and development positions of increasing responsibility at Syntex Corporation, including Vice President and Director of the Institute for Clinical Medicine. Dr. Yee received his bachelor’s degree from the University of California at Berkeley in electrical engineering and computer science. Dr. Yee went on to earn a PhD in biophysics at University of California at Berkeley. He attended the University of California, Los Angeles School of Medicine, where he earned his medical degree, and he is board certified in internal medicine.